New facility will manufacture active pharmaceutical ingredients for medicines like Foundayo (orforglipron), strengthening domestic supply chain

Site will employ more than 600 people in high-wage jobs

$12.5 million in support to build talent pipeline, workforce training center with San Jacinto College

HOUSTON, Sept. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) broke ground today in Houston, Texas, one of ten U.S. manufacturing sites — and fifth location to produce domestic active pharmaceutical ingredients (API) — announced since 2020. As part of the company's $50 billion push to reshore medicine production to meet growing demand at home and export American-made medicines to people around the world, the $6.5 billion Houston site will manufacture Foundayo (orforglipron), Lilly's first synthetic oral GLP-1 medicine, along with other small-molecule medicines and advanced therapeutics.

Foundayo is a GLP-1 receptor agonist approved in the U.S. for weight management in adults with obesity, or adults with overweight and a weight-related condition. It is a small molecule rather than a peptide; small molecules are manufactured using more well-established technologies and therefore can be more readily scalable. Foundayo is currently under regulatory review in more than 40 countries, with a full global rollout targeted for 2027. Lilly is also studying Foundayo for other uses, including type 2 diabetes and obstructive sleep apnea, with data expected later this year.

David A. Ricks, Lilly Chair and CEO: "We are thrilled to break ground on our latest 'medicines made in America' site in the great state of Texas. This $6.5B investment will help change the game for tens of millions of people suffering from overweight, obesity and its consequences like diabetes. We will make and ship Lilly's latest products from Texas to people here at home and around the world."

Building a talent pipeline in Houston

Lilly is providing $12.5 million to support a relationship with San Jacinto College to give Houstonians a pathway into advanced chemical synthesis manufacturing careers, with no prior experience required. This relationship will focus on developing training pathways and expanding the equipment and facility capacity needed to produce technicians, operators, maintenance professionals, and other manufacturing talent, while also leveraging Lilly experts to support curriculum development and instructor readiness and preparation. Separately, Lilly is providing a $2.5 million charitable donation to the San Jacinto College Foundation to support scholarships for eligible students.

Lilly is currently hiring in Houston and expects the new facility to create more than 600 high-wage jobs like engineers, scientists, operations personnel, and lab technicians — along with 4,000 construction jobs as the site is being built and brought online. Visit the Lilly Houston career page for open positions or join Lilly's talent community for future opportunities.

Edgardo Hernandez, Executive Vice President and President of Lilly Manufacturing Operations: "When you invest in a place like Houston, you invest in its people first. This facility will run on the talent of this community, powered by our relationship with San Jacinto College. We're hiring across the greater Houston area to help residents build careers close to home. The facility itself is being built to the highest standards for safety, quality and responsible stewardship of the environment, and every one of these jobs helps bring innovative medicines to the patients counting on them."

In addition to Foundayo, the Houston site will focus on advanced therapeutics that were not within reach even a few years ago. This will include oligonucleotides, a class of medicines that can work at the genetic level to switch off the production of specific proteins to treat disease closer to its source.

Texas Governor Greg Abbott: "Texas is the global hub for life sciences. This $6.5 billion Lilly investment in Houston is the largest active pharmaceutical ingredient project in Texas history and will create more than 600 high-wage jobs, right here in Texas. Texas will produce these medicines at home so we can deliver life-changing treatments to millions of Americans."

Producing this pipeline of medicines at scale requires manufacturing capacity built to match the pace of innovation. Lilly has announced ten U.S. sites since 2020:

The Houston site will use state-of-the-art technologies, including machine learning, AI, digitally integrated systems and advanced data analytics to drive right-first-time execution. Digital automation will be embedded throughout the site to streamline operations and ensure a reliable supply of safe, high-quality medicines.

Additional quotes for media use

Dr. Brenda Hellyer, Chancellor of San Jacinto College: "Eli Lilly's manufacturing investment in Generation Park is a tremendous opportunity for the Houston region. San Jacinto College is proud to work with Lilly to develop the skilled workforce needed to support the growth of biopharmaceutical manufacturing. Together, we will expand industry-informed education and hands-on training pathways that prepare students and incumbent workers with the technical skills these advanced manufacturing careers require. This relationship will build a strong, sustainable talent pipeline for Lilly while creating meaningful, high-demand career opportunities across our region."

For media use:

About Foundayo™ (orforglipron)

Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day with no planning around food or drink.2 Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orfoglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.

INDICATION AND SAFETY SUMMARY WITH WARNINGS

Foundayo™ (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

Warnings — Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

Common side effects

The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking Foundayo

Review these questions with your healthcare provider:

How to take

Learn more

Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.

OLIVE TREE PEOPLE'S FIRST OLIVE GROVES SUCCESSFULLY COMPLETE THEIR DEMETER AUDIT — PLACING THE WATERLESS BEAUTY PIONEER AMONG A VERY SMALL GROUP OF BEAUTY COMPANIES WORLDWIDE WITH THEIR OWN BIODYNAMIC AGRICULTURAL RESOURCES AT THE SOURCE OF THEIR BEAUTY.

ANDALUSIA, Spain, Sept. 21, 2026 /PRNewswire/ -- Most beauty companies buy ingredients.

OLIVE TREE PEOPLE grows them.

And very few beauty companies in the world can say what OLIVE TREE PEOPLE can say today:

Our beauty begins on our own land, with our own trees — and our first olive groves have now successfully completed their Demeter audit with outstanding results.

Formal certification is pending completion of the certification process.

This places OLIVE TREE PEOPLE among a remarkably small group in the global beauty industry: companies whose relationship with nature doesn't begin with purchasing a botanical ingredient from a supplier, but with their own agricultural resources at the very source.

For more than 20 years, OLIVE TREE PEOPLE has cultivated and protected mountain olive trees in Andalusia, Spain — not simply as inspiration for its products, but as the agricultural origin of its beauty philosophy and many of its most important ingredients.

The company doesn't simply know where its ingredients come from.

It knows the land.

It knows the trees.

It grows them.

For OLIVE TREE PEOPLE, agriculture has never been a supplier story.

IT IS WHERE BEAUTY BEGINS.

The soil.

The trees.

The leaves.

The olives.

The harvest.

The extraction.

The formulation.

The skin.

One living cycle.

FROM A DEMETER FARM AT 16 TO HIS OWN OLIVE GROVES

For founder Thomas Lommel, the moment closes a circle that began decades before OLIVE TREE PEOPLE existed.

At 16, while attending a Waldorf school in Germany, Lommel completed his first agricultural internship on a Demeter farm.

What began there as an encounter with a radically different understanding of agriculture — one in which soil, plants, animals and people are understood as parts of one living agricultural organism — would eventually become part of the philosophy behind his life's work.

Years later, that journey led him to the mountain olive trees of Andalusia.

And ultimately to OLIVE TREE PEOPLE.

"We do not take from nature and then attempt to give something back. We create a living cycle."

That distinction is fundamental.

The olive groves are not a sustainability project attached to a beauty company.

They are part of the beauty company.

OLIVE TREE PEOPLE grows and protects its own olive trees, works with their leaves and olives, extracts bioactive substances at the heart of its formulations, and develops Waterless Beauty around the olive tree rather than around water as the primary ingredient.

BEAUTY HAS TALKED ABOUT FARM-TO-FACE.

OLIVE TREE PEOPLE ACTUALLY OWNS THE FARM.

Traceability has become a major word in beauty.

Brands talk about knowing where an ingredient was grown.

OLIVE TREE PEOPLE goes considerably further.

The company is vertically connected all the way back to the living tree.

From its own agricultural resources in Andalusia to extraction, formulation and finally the skin, the company is building a beauty model in which agriculture isn't hidden somewhere at the beginning of a supply chain.

Agriculture is part of the brand itself.

And now, with its first olive groves successfully completing their Demeter audit, that agricultural foundation is moving toward one of the world's most demanding biodynamic standards.

For Lommel, this isn't a new sustainability strategy.

It is the continuation of an idea that began when he was 16.

Beauty shouldn't take something from nature and later ask how to compensate for it.

BEAUTY CAN BE A CIRCLE FROM THE BEGINNING.

So perhaps this isn't really about passing an audit.

It's about something much bigger:

One of the very few beauty companies in the world with its own agricultural resources taking those resources to an extraordinary biodynamic standard.

Rooted.

Living.

Circular.

And beginning with its own trees.

ABOUT OLIVE TREE PEOPLE

OLIVE TREE PEOPLE is a pioneer and leading force in waterless beauty. Instead of using the conventional water phase found in most skincare products, the company replaces water with its proprietary olive leaf cell elixir and combines it with powerful olive-tree ingredients, including hydroxytyrosol.

Founded by olive tree farmer Thomas Lommel, OLIVE TREE PEOPLE develops skincare, beauty and holistic experiences based on more than 20 years of work with mountain olive trees and the principles of Olive Tree Therapy.

ABOUT OLIVEDA INTERNATIONAL, INC.

Oliveda International, Inc. and its subsidiary, Olive Tree People Inc., together with the European companies Olive Tree People Europe AG, Oliveda Deutschland GmbH and Olive Tree Farmers SL, were founded by German real estate investor Thomas Lommel.

Lommel has more than 20 years of experience in the management and organic certification of mountain olive tree cultivation; the extraction of first-class, internationally award-winning extra virgin olive oils and hydroxytyrosol; and the production and distribution of cosmetic and holistic waterless products related to the olive tree.

Lommel is the inventor of Olive Tree Therapy 10 Years in 14 Days and of olive matcha, which is based on ground olive leaf. He also developed a unique coffee replacement based on olive leaf and hydroxytyrosol. In addition, Lommel is successfully active in the rapidly growing mindfulness industry through the olive tree sound bath meditation he developed and the frequencies of his olive trees, which he makes available worldwide.

OLIVE TREE PEOPLE's registered beauty brands include OLIVEDA, LA DOPE, OLIVE ROSE, OLIVE MUSH, IS THAT MATTY? and OLIVE re:connected to nature.

Lommel is also the region's largest conservationist and protector of more than 30,000 one-hundred-year-old mountain olive trees. Through the Thomas Lommel Foundation, he brings the water that he does not use in his waterless beauty products to the people of Africa by building water wells on site.

In addition to online sales, Oliveda Deutschland GmbH operates its own flagship stores in Berlin and Düsseldorf.

The brand's treatment concepts are unique worldwide, and their effectiveness has been confirmed by conventional medicine. The story is documented in the book The Olive Tree Therapy 10 Years in 14 Days.

Waterless Beauty has been called "The Next Big Thing" in articles in U.S. Vogue, Harper's Bazaar, InStyle, ELLE, Madame, Forbes and many other industry publications, as well as by Mintel, a world-leading futurology institute. Gigi Hadid and many other celebrities are already OLIVEDA fans and support its success.

Further information on Oliveda International, Inc. and its subsidiaries and associate companies and brands can be found at www.olivetreepeople.com.

SOURCE Olive Tree People

Share this article

NEW YORK, Sept. 21, 2026 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of J.B. Hunt Transport Services, Inc. (NASDAQ: JBHT) resulting from allegations that J.B. Hunt may have issued materially misleading business information to the investing public.

So What: If you purchased J.B. Hunt securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/cases/jb-hunt-transport-services-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On September 16, 2026, CNBC published an article entitled "J.B. Hunt stock plunges 10% after company warns third-quarter earnings will fall." The article further stated that J.B. Hunt's Chief Financial Officer had "said between costs for recruiting, advertising, onboarding, training and sign-on bonuses, the company expects to see about $25 million more in the third quarter compared with the second quarter."

On this news, J.B. Hunt shares fell sharply in intraday trading on September 16, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY 10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     [email protected]

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

ORLANDO, Fla., Sept. 21, 2026 /PRNewswire/ -- Xenia Hotels & Resorts, Inc. (NYSE: XHR) ("Xenia" or the "Company") today announced that its Board of Directors authorized a cash dividend of $0.14 per share of the Company's common stock for the third quarter 2026. The dividend will be paid on October 15, 2026 to all holders of record of the Company's common stock as of the close of business on September 30, 2026.

About Xenia Hotels & Resorts, Inc.

Xenia Hotels & Resorts, Inc. is a self-advised and self-administered REIT that invests in uniquely positioned luxury and upper upscale hotels and resorts with a focus on the top 25 lodging markets as well as key leisure destinations in the United States. The Company owns 29 hotels and resorts comprising 8,783 rooms across 14 states. Xenia's hotels are in the luxury and upper upscale segments, and are operated and/or licensed by industry leaders including Marriott, Hyatt, Kimpton, Fairmont, Loews, Hilton, and Davidson. For more information on Xenia's business, refer to the Company website at www.xeniareit.com.

For additional information or to receive press releases via email, please visit our website at 

www.xeniareit.com

SOURCE Xenia Hotels & Resorts, Inc.

Share this article

Drayton Valley, Alberta, selected to receive multi-year investment through the company's Thrive program

SEATTLE, Sept. 21, 2026 /PRNewswire/ -- Weyerhaeuser Company (NYSE: WY) today announced a commitment to invest $1 million in Drayton Valley, Alberta, through the company's Thrive program. The investment will be made over the next several years with input from local elected officials, business leaders, nonprofits, employees and other community partners. Drayton Valley is the first community in Canada to be selected for the program, reflecting the company's long-term commitment to its Canadian operations.

"We have a responsibility to our rural operating communities to help them remain great places to live, work and do business for generations to come, and we launched our Thrive program several years ago to amplify the positive impact and support we can provide locally," says Devin W. Stockfish, president and chief executive officer. "We're looking forward to working with community leaders in Drayton Valley to address priority needs and provide meaningful long-term benefits."

Drayton Valley is a community of approximately 8,000 people located about 90 minutes southwest of Edmonton. Weyerhaeuser, which operates six manufacturing facilities across Canada, has operated a sawmill in Drayton Valley for nearly 40 years and in 2013 announced a $23 million investment in production upgrades. Today, the company employs approximately 450 people through its sawmill and surrounding forestry operations, making Weyerhaeuser the largest employer in the region.

"Weyerhaeuser is an important part of our community and a respected industry leader whose longstanding presence, investment and support continue to make a meaningful difference in Drayton Valley and the surrounding area," says Nancy Dodds, mayor of Drayton Valley. "We are deeply grateful for the strong partnership and trusted relationship we have built over the years, and we are thrilled to have been selected for this opportunity through the Thrive program. We look forward to working alongside Weyerhaeuser leaders and community members to identify our highest priorities and ensure this investment has a lasting impact as we build a stronger, healthier and more resilient future together."

Weyerhaeuser's Thrive program is a key pillar of the company's broader 3 by 30 Sustainability Ambition around rural communities and goes far beyond the financial investment. In selected communities, Weyerhaeuser leaders engage deeply with local stakeholders to identify and prioritize the challenges to be addressed through long-term collaboration, investment and advocacy. Potential opportunities in Drayton Valley will be explored by Weyerhaeuser and community leaders in the weeks and months ahead.

"We're here to listen to the needs of the community and work with local stakeholders, including our employees, to understand where we can make the biggest impact together," says Nancy Thompson, senior director of Advocacy and Philanthropy. "We'll be reaching out to community organizations and partners in the coming weeks to understand where our investment can make the biggest difference."

Each of Weyerhaeuser's three previously announced Thrive communities — Zwolle, Louisiana (2023), Raymond, Washington (2024), and Buckhannon, West Virginia (2025) — identified different priorities for investment. In Zwolle, improvements to local ballfields have been completed, and significant progress has been made in upgrading the city's water infrastructure. In Raymond, a workforce housing initiative launched earlier this year, and in Buckhannon, early discussions have focused on educational opportunities with a potential to improve STEAM education.

Weyerhaeuser launched Thrive in 2023 to provide additional resources and support to five of its rural operating communities across North America. Weyerhaeuser plans to announce its fifth Thrive community, completing the company's initial program commitment, later this year. Selected communities represent areas where Weyerhaeuser has a significant presence and a history of employee and leadership engagement; where there are opportunities to take advantage of external resources, such as federal or state/provincial infrastructure grants, to strengthen advocacy efforts; and where Weyerhaeuser can partner with other employers, nonprofits and community leaders to amplify efforts and impact on the ground.

ABOUT WEYERHAEUSER

Weyerhaeuser Company, one of the world's largest private owners of timberlands, began operations in 1900 and today owns or controls more than 10 million acres of timberlands in the U.S., as well as additional public timberlands managed under long-term licenses in Canada. Weyerhaeuser has been a global leader in sustainability for more than a century and manages 100 percent of its timberlands on a fully sustainable basis in compliance with internationally recognized sustainable forestry standards. Weyerhaeuser is also one of the largest manufacturers of wood products in North America and operates additional business lines around product distribution, climate solutions, real estate, energy and natural resources, among others. In 2025, the company generated $6.9 billion in net sales and employed approximately 9,500 people who serve customers worldwide. Operated as a real estate investment trust, Weyerhaeuser's common stock trades on the New York Stock Exchange under the symbol WY. Learn more at www.weyerhaeuser.com.

For more information contact:

Analysts – Andy Taylor, 206-539-3907

Media – Nancy Thompson, 919-861-0342

SOURCE Weyerhaeuser Company

Share this article

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

– Completion of BLA submission expected in Q4 2026 –

WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease. A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.

"Our team looks forward to completing the ST-920 BLA submission and potentially bringing a one-time administered, safe and effective durable disease treatment that addresses the limitations of chronic enzyme replacement therapy to the Fabry community," said Matthew B. Klein, M.D., Chief Executive Officer.

About ST-920

ST-920 or isaralgagene civaparvovec is a one-time administered AAV gene therapy product candidate for the treatment of Fabry disease. In clinical studies, isaralgagene civaparvovec enabled long-term production of the deficient alpha-galactosidase A (α-Gal A) enzyme and significant reduction in globotriaosylceramide (Gb3) levels with durable clinical benefit and reduction of the burden associated with chronic Enzyme Replacement Therapy (ERT). The FDA has granted Orphan Drug, Fast Track, and RMAT designations to isaralgagene civaparvovec, which has also received Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from the U.K. Medicines and Healthcare products Regulatory Agency. 

About Fabry Disease

Fabry disease is a lysosomal storage disorder caused by mutations in the galactosidase alpha gene (GLA), which leads to deficient alpha-galactosidase A (α-Gal A) enzyme activity, which is necessary for metabolizing globotriaosylceramide (Gb3). The buildup of Gb3 in the cells can cause serious damage to vital organs, including the kidney, heart, nerves, eyes, gut and skin. Symptoms of Fabry disease can include decreased or absent sweat production, heat intolerance, angiokeratoma (skin blemishes), vision problems, kidney disease, heart failure, gastrointestinal disturbance, mood disorders, neuropathic pain and tingling in the extremities.

About PTC Therapeutics, Inc.

PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders.

For more information please contact:

Investors:

Ellen Cavaleri

+1 (615) 618-6228

[email protected] 

Media:

Jeanine Clemente

+1 (908) 912-9406

[email protected] 

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the Company's expectations regarding the anticipated benefits of ST-920; the timing of and potential for regulatory submissions and potential commercial launch for ST-920; and PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance," "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," "aim," and similar expressions.

PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: PTC's ability to complete the BLA submission and obtain regulatory approval for and then commercialize ST-920; the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to Sephience, including commercialization and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in geographies in which it has been approved and the effect of the European Commission's adoption of the negative opinion from the Committee for Medicinal Products for Human Use (CHMP) on Translarna and the withdrawal of the Translarna NDA in the US on other regulatory bodies; expectations with respect to PTC's license and collaboration agreement with Novartis Pharmaceuticals Corporation for votoplam for the treatment of Huntington's disease including its right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis, the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses, including potential accelerated approval; expectations with respect to ST-920, including the potential achievement of regulatory milestone payments that PTC may be obligated to make; expectations with respect to Upstaza/Kebilidi, including commercialization, manufacturing capabilities, and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to vatiquinone, including with respect to the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses and potential approvals and other matters; expectations with respect to the commercialization of Evrysdi under PTC's SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; expectations regarding PTC's product candidates, including the timing of clinical trials and studies; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; PTC's ability to satisfy its obligations under the terms of its lease agreements; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Sephience, Translarna, Emflaza, Upstaza, Kebilidi, Evrysdi, Tegsedi, Waylivra or ST-920.

The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

SOURCE PTC Therapeutics, Inc.

Share this article

TORONTO, Sept. 21, 2026 /PRNewswire/ -- Sun Life Financial Inc. (TSX: SLF) (NYSE: SLF) ("Sun Life") today announced that 1,400 of its 6,838,672 Class A Non-cumulative Rate Reset Preferred Shares Series 10R (the "Series 10R Shares") have been elected for conversion on September 30, 2026, on a one-for-one basis, into Class A Non-cumulative Floating Rate Preferred Shares Series 11QR (the "Series 11QR Shares"), and 621,829 of its 1,161,328 Series 11QR Shares have been elected for conversion on September 30, 2026 on a one-for-one basis into Series 10R Shares.

Since there would be less than 1,000,000 Series 11QR Shares outstanding on September 30, 2026, after taking into account all such election notices received by the September 16, 2026 deadline for conversion, (i) Sun Life will automatically convert all remaining Series 11QR Shares into Series 10R Shares, on a one-for-one basis, on September 30, 2026, and (ii) the holders of Series 10R Shares are not entitled to convert their Series 10R Shares into Series 11QR Shares.

Consequently, on September 30, 2026, Sun Life will have 8,000,000 Series 10R Shares issued and outstanding and nil Series 11QR Shares issued and outstanding. The Series 10R Shares are listed on the Toronto Stock Exchange under the symbol SLF.PR.H.

As announced by Sun Life on August 31, 2026, commencing as of September 30, 2026, holders of Series 10R Shares will be entitled to receive non-cumulative preferential cash dividends on a quarterly basis, as and when declared by the Board of Directors of Sun Life and subject to the Insurance Companies Act (Canada). The dividend rate for the five-year period commencing on September 30, 2026 to but excluding September 30, 2031 will be 5.519% per annum or $0.344938 per share per quarter, being equal to the sum of the Government of Canada Yield, as defined in the terms of the Series 10R Shares, on Monday, August 31, 2026 plus 2.17%, as determined in accordance with the terms of the Series 10R Shares.

Subject to regulatory approval, Sun Life may redeem all or any part of the outstanding Series 10R Shares, at Sun Life's option, by the payment of an amount in cash for each share so redeemed of $25.00, together with all declared and unpaid dividends to the date fixed for redemption, on September 30, 2031 and on September 30 in every fifth year thereafter.

The Series 10R Shares and the Series 11QR Shares have not been and will not be registered under the United States Securities Act of 1933, as amended, and subject to certain exceptions, may not be offered, sold or delivered, directly or indirectly, in the United States of America for the account or benefit of U.S. persons. This release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

About Sun Life

Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of June 30, 2026, Sun Life had total assets under management of $1.70 trillion. For more information, please visit sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.

Note to editors: All figures in Canadian dollars

To contact Sun Life media relations, please email [email protected]

To contact Sun Life investor relations, please email [email protected]

SOURCE Sun Life Financial Inc. - Financial News

Share this article

TAIPEI, Sept. 21, 2026 /PRNewswire/ -- EVA Air once again earned top honors at the prestigious SKYTRAX World Airline Awards, taking first place in three categories: World's Best Premium Economy Class, World's Best Premium Economy Class Airline Amenities, and World's Most Family Friendly Airline. Overall, EVA Air secured a total of 18 TOP Ten rankings across various award categories, including these three No.1 honors. The carrier also retained its coveted SKYTRAX 5-Star Airline rating for the 11th consecutive year, reaffirming its longstanding commitment to excellence in safety and service.

"We are grateful to travelers around the world and to SKYTRAX for this recognition," said EVA Air Chief Executive Vice President Albert Liao. "Maintaining our SKYTRAX 5-Star Airline rating for 11 consecutive years while once again receiving top honors across multiple categories is an achievement we are incredibly proud of. These awards reflect the dedication and professionalism of every member of the EVA Air team and their unwavering commitment to our passengers. Guided by our core values of safety, service, and sustainability, we will continue investing in every aspect of the travel journey while delivering the safe, comfortable, and five-star service experience that travelers expect from EVA Air."

Edward Plaisted, CEO of SKYTRAX said, "We congratulate EVA Air on the fabulous achievement of being named the World's Most Family Friendly Airline, which recognizes EVA Air's efforts to create a more seamless and relaxing experience for passengers traveling with children. EVA Air was the pioneer airline to introduce Premium Economy back in 1992, and at a time when this cabin class is the fastest growing cabin category, it is heartening to see EVA Air maintaining their excellence by winning the Award for the World's Best Premium Economy Class Cabin."

Established in 1999, the SKYTRAX World Airline Awards are widely regarded as one of the aviation industry's most prestigious honors. The awards are based on a global passenger satisfaction survey that evaluates airline products and services, with questionnaires available in multiple languages, including English, French, Spanish, Japanese, and Chinese. The results are closely followed by the global aviation and travel industries and serve as an important benchmark for travelers worldwide.

EVA Air has repeatedly won SKYTRAX "Global Airline Awards." Its rankings and the associated categories are:

In addition to maintaining its SKYTRAX 5-Star Airline rating for an 11th consecutive year and earning multiple World Airline Awards, EVA Air has received a series of other international accolades in 2026. Travel + Leisure named EVA Air the No. 1 International Airline in its 2026 rankings. The carrier was also ranked 11th among AirlineRatings.com's World's Top 25 Airlines and 8th among the World's 25 Safest Airlines, while earning the organization's highest 7-Star PLUS safety rating.

As part of its ongoing efforts to enhance the passenger experience and expand its global network, EVA Air will launch a new nonstop service from Taipei to Delhi on December 1. Operating five flights per week using Airbus A330-300 aircraft, the new route will make EVA Air the only Taiwan-based airline offering nonstop passenger service to India.

About EVA Air:

A Star Alliance member, EVA Air was founded in 1989 as Taiwan's first privately owned international airline. It is an affiliated company to global container-shipping leader Evergreen Line. It flies a fleet of more than 80 Boeing and Airbus aircraft to around 60 international destinations throughout Asia, Oceania, Europe, and North America. Travelers can learn more about EVA Air and schedules, book, and buy tickets at www.evaair.com.

SOURCE EVA Airways Corporation

Share this article

Construction Partners, Inc. Completes Florida Acquisition

Transaction Expands Company's Operations in Florida Panhandle

DOTHAN, Ala., Sept. 21, 2026 /PRNewswire/ -- Construction Partners, Inc. (NASDAQ: ROAD) ("CPI" or the "Company"), a vertically integrated civil infrastructure company specializing in the construction and maintenance of roadways in local markets across the Sunbelt, today announced that it has acquired Roads, Inc. of NWF ("Roads, Inc."), an asphalt manufacturing and construction business headquartered in Cantonment, Florida. Roads, Inc. provides asphalt paving, roadway construction and disaster response debris removal services throughout Florida, Alabama and the southeastern United States. In connection with the transaction, CPI acquired a hot-mix asphalt plant strategically located north of Pensacola, together with related crews and equipment. The acquired operations will become part of CPI's Florida platform company, C.W. Roberts Contracting, Incorporated ("CWR").

Fred J. (Jule) Smith, III, the Company's President and Chief Executive Officer, said, "We are pleased to welcome the Roads, Inc. team to the CPI family of companies. This transaction expands CWR's operations in the Florida Panhandle and enhances our ability to serve public and private infrastructure customers throughout this growing region. Roads, Inc.'s strategically located hot-mix asphalt plant, as well as its experienced workforce, construction capabilities and established local relationships, will complement CWR's existing operations and position us to better serve customers across the Panhandle and beyond. We welcome more than 150 talented new employees to CWR and look forward to building upon Roads, Inc.'s reputation for quality work and reliable service as part of our family of companies."

About Construction Partners, Inc.

Construction Partners, Inc. is a vertically integrated civil infrastructure company operating in local markets throughout the Sunbelt in Alabama, Florida, Georgia, North Carolina, Oklahoma, South Carolina, Tennessee and Texas. Supported by its hot-mix asphalt plants, aggregate facilities and liquid asphalt terminals, CPI focuses on the construction, repair and maintenance of surface infrastructure. Publicly funded projects make up the majority of its business and include local and state roadways, interstate highways, airport runways and bridges. The company also performs private sector projects that include paving and sitework for office and industrial parks, shopping centers, local businesses and residential developments. To learn more, visit www.constructionpartners.net.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained herein that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Securities Exchange Act of 1934. These statements may be identified by the use of words such as "seek," "continue," "estimate," "predict," "potential," "targeting," "could," "might," "may," "will," "expect," "should," "anticipate," "intend," "project," "outlook," "believe," "plan" and similar expressions or their negative. The forward-looking statements contained in this press release include, without limitation, statements relating to the benefits of a business acquisition and the expected results of the acquired business. These and other forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could significantly affect expected results. Important factors that could cause actual results to differ materially from those expressed in the forward-looking statements are set forth in the Company's most recent Annual Report on Form 10-K, its subsequent Quarterly Reports on Form 10-Q, its Current Reports on Form 8-K and other reports the Company files with the SEC. Forward-looking statements speak only as of the date they are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such statements except to the extent required by applicable law.

Contact:

Rick Black

Investor Relations

[email protected]

(713) 529-6600

SOURCE Construction Partners, Inc.

Share this article

Unveils Refreshed Brand Identity to Reflect Its Evolution

WINNEMUCCA, Nev., Sept. 21, 2026 /PRNewswire/ -- Hycroft Mining Holding Corporation (Nasdaq: HYMC) ("Hycroft" or the "Company"), a U.S.-based gold and silver exploration and development company that owns the Hycroft Mine, today provides an update on the technical initiatives underway to advance the mine toward production. The Company also unveils a refreshed brand identity, redesigned website and updated corporate presentation that reflect Hycroft's transformation and the significant opportunities being advanced across the asset.

The Company is continuing to evaluate multiple potential pathways to unlock shareholder value in the second half of 2026. These efforts are supported by a senior leadership team with extensive operational expertise and a strengthened Board of Directors with substantial experience in mining operations and project development. The updated website, available today at www.hycroftmining.com, provides investors and all stakeholders with enhanced access to information on the Company's strategy, technical programs, exploration results and corporate developments.

Diane Garrett, Executive Chairman and CEO, commented: "We are progressing underground development planning at Brimstone and Vortex, completing trade-off study results between pressure oxidation and roasting for the broader sulfide resource and assessing the potential restart of heap leach operations. Additionally, we are awaiting two additional core rigs and expect to have them in the fourth quarter to accelerate drilling on Vortex and Brimstone and test other highly prospective targets across the site. Our focus remains on defining the optimal path to production that delivers the highest economic value from the asset to our shareholders.

We have also strengthened our Board and management team with highly experienced mining leaders who bring the operating, technical, financial and strategic capabilities needed to support this next phase of growth and our updated website and corporate materials provide a more effective platform to communicate the progress being made across the asset."

Technical Update

Assessment of High-Grade Underground Development Potential

The Company is finalizing its internal assessment of potential underground development options for the high-grade Brimstone and Vortex systems. As previously announced, the Company engaged RESPEC Company LLC ("RESPEC") to evaluate underground mining alternatives and develop a conceptual mine plan. RESPEC is also supporting an assessment of potential locations and configurations for an exploration decline that could provide underground drill access to more effectively and efficiently explore and expand the high-grade systems while also considering its potential integration into a future underground mining operation.

Hatch Ltd. ("Hatch") has also been engaged to evaluate processing alternatives for recovering silver and gold from a potential underground operation. A metallurgical test program is underway at Hazen Research Inc. ("Hazen") to further characterize the metallurgical response of the high-grade Brimstone and Vortex material and support this evaluation.

In parallel, the Company will continue the engineering, environmental, and permitting work required to advance the project along the optimal production path.

Metallurgical Test Work on Roasting

The Company has completed the roasting metallurgical test program and is now finalizing a trade-off analysis comparing the economic benefit of both roasting and pressure oxidation. While both processing options are conventional methods, roasting has the potential for an additional revenue stream through the production and sale of sulfuric acid, which is a critical input for lithium, copper, and fertilizer production.

Assessment of a Heap Leach Restart

The Company continues to evaluate the potential to restart heap leach operations at Hycroft. A reverse circulation drill program, initiated in late 2025, further defined the quantity, location and characteristics of oxide and transition material. A metallurgical test program is underway, after which the Company will evaluate the appropriate next steps for advancing the restart opportunity.

About Hycroft Mining Holding Corporation

Hycroft Mining Holding Corporation is a US-based gold and silver company exploring and developing the Hycroft Mine, among the world's largest precious metals deposits, located in Nevada, a Tier-1 mining jurisdiction. With a long history of heap leach operations, Hycroft is advancing to the next phase of operations for processing sulfide mineralization. In addition, Hycroft is engaged in a robust exploration drill program (2025-2026 Exploration Drill Program) to expand and advance the two new high-grade silver systems Brimstone and Vortex. These discoveries represent a significant value driver for the Hycroft Mine.

For Further Information

Investor Relations:

E: [email protected]

P: 775-245-0564 

Media:

E: [email protected]

P: 775-245-0564 

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release and in public statements by our officers or representatives that address activities, events or developments that we expect or anticipate will or may occur in the future are forward-looking statements. These include, but are not limited to, statements regarding future business strategy, plans and goals, competitive strengths, the advancement and development of the Hycroft Mine, the results and implications of metallurgical analysis and test work, and the expansion and growth of our business.

Forward-looking statements are often identified by future or conditional words such as "estimate," "plan," "anticipate," "expect," "intend," "believe," "target," "budget," "may," "can," "will," "would," "could," "should," "seeks," "scheduled to" and similar words or expressions but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties, which could cause actual results to differ materially from those reflected in the statements. The risks include, but are not limited to: (i) risks related to changes in our operations at the Hycroft Mine, including risks associated with the cessation of mining operations at the Hycroft Mine; uncertainties concerning estimates of mineral resources; risks related to the lack of a completed feasibility study; risks related to metallurgical test work and process development; risks related to obtaining and maintaining necessary permits and regulatory approvals; and risks related to our ability to re-establish commercially feasible mining and processing operations; and (ii) industry-related risks, including fluctuations in the price of gold and silver; the commercial success of, and risks related to, our exploration and development activities; uncertainties and risks related to our reliance on contractors and consultants; and the availability and cost of equipment, supplies, energy or reagents.

These and other risks may cause actual results to differ materially from those expressed or implied by the forward-looking statements, and the occurrence of one or more of these events or circumstances, alone or in combination with others, may have a material adverse effect on our business, cash flows, financial condition and results of operations. Please see the "Risk Factors" outlined in our Annual Report on Form 10-K for the year ended December 31, 2025, and in other reports filed with the SEC, for more information about these and other risks. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

SOURCE Hycroft Mining Holding Corporation

Share this article